Aquestive Therapeutics (AQST)
(Delayed Data from NSDQ)
$4.07 USD
+0.14 (3.56%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $4.02 -0.05 (-1.23%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth C Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
AQST 4.07 +0.14(3.56%)
Will AQST be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for AQST based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AQST
Aquestive Therapeutics (AQST) Ascends While Market Falls: Some Facts to Note
Aquestive Therapeutics (AQST) Flat As Market Sinks: What You Should Know
AQST: What are Zacks experts saying now?
Zacks Private Portfolio Services
Aquestive (AQST) Up as Anaphylm Pivotal Study Meets Goals
Strength Seen in Aquestive Therapeutics (AQST): Can Its 16.0% Jump Turn into More Strength?
Aquestive Therapeutics (AQST) Reports Q4 Loss, Tops Revenue Estimates
Other News for AQST
Aquestive Therapeutics Receives U.S. FDA Approval and Market Access for Libervantâ„¢ (diazepam) Buccal Film in Pediatric Patients Ages 2 to 5 and Provides Update on Anaphylmâ„¢ (epinephrine) Sublingual Film
Aquestive Therapeutics receives FDA approval, market access for Libervant
Buy Rating Affirmed for Aquestive Therapeutics Following FDA Approval and Growth Prospects
Aquestive wins FDA approval for anti-seizure therapy Libervant
Aquestive Therapeutics to Report First Quarter 2024 Financial Results and Recent Business Highlights on May 7 and Host Conference Call on May 8 at 8:00 a.m. ET